Articles From: AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference to Acorda Therapeutics Reports Second Quarter 2014 Financial Results


REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference investment picks
PORT WASHINGTON, N.Y., July 30, 2014 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, has appointed Daniel Yarosh, Ph.D., 60 years old to its Board of Directors, effective July 29, 2014.
Sign-up for ACETO Appoints Daniel Yarosh, Ph.D. to the Board of Directors investment picks
PORT WASHINGTON, N.Y., Sept.
Sign-up for ACETO Board of Directors Declares Quarterly Cash Dividend investment picks
PORT WASHINGTON, N.Y., Aug.
Sign-up for ACETO Corporation Schedules Fourth Quarter & Fiscal 2014 Financial Results News Release and Conference Call investment picks
PORT WASHINGTON, N.Y., Sept.
Sign-up for ACETO Reports Fiscal 2014 Fourth Quarter and Year End Results investment picks
SOUTH SAN FRANCISCO, Calif., Aug.
Sign-up for Achaogen Announces Second Quarter 2014 Results investment picks
SOUTH SAN FRANCISCO, Calif., July 14, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO) , a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced the appointment of Ian Friedland, M.D. as its Chief Medical Officer.
Sign-up for Achaogen Appoints Dr. Ian Friedland as Chief Medical Officer investment picks
2014/7/1
--$100,000 World of Difference grant will fund research lacking today --1 in 68 U.S. children is on the autism spectrum, up tenfold in 40 years --Half of children with autism at risk for disease, depression --Running may hold key to better development for children with autism BLOOMFIELD, Conn.
Sign-up for Achilles Receives Cigna Foundation Grant to Study Effect of Running on Autism investment picks
NEW HAVEN, Conn., Aug.
Sign-up for Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors investment picks
NEW HAVEN, Conn., July 1, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that it has been added to the Russell 2000 and Russell Microcap Indexes.
Sign-up for Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes investment picks
NEW HAVEN, Conn., Aug.
Sign-up for Achillion Reports Second Quarter and Six Month 2014 Financial Results investment picks
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , today announced an open call for submissions to the 2015 ACI Innovation Awards .
Sign-up for ACI Worldwide Announces Call for Entries for 2015 ACI Innovation Awards investment picks
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , announced today that it has completed the acquisition of Retail Decisions (ReD) , a leader in fraud prevention solutions.
Sign-up for ACI Worldwide Completes Acquisition of Retail Decisions (ReD) investment picks
ACI Worldwide (NASDAQ: ACIW), a leading international provider of electronic payment and banking solutions , has been recognized as an industry leader by Aite Group, an independent research firm, in its recent report, “2014 Evaluation of Leading Cash Management Providers.” According to the report, “the U.S. cash management industry is ready for change, and investment in the online and mobile channels is critical to future success.” ACI has seen considerable momentum for its online banking platform, and as the report notes, ACI had the highest number of customers in terms of large and midsize U.S. banks (banks with greater than US$10 billion in assets). ACI recently announced that Webster Bank, a leading regional bank in the Northeast with $21 billion in assets, has selected the company to host its online banking platform.
Sign-up for ACI Worldwide Recognized as Industry Leader in Aite Group’s Evaluation of Leading Cash Management Providers investment picks
ACI Worldwide (NASDAQ: ACIW), a leading international provider of electronic payment and banking solutions , welcomes financial thought leaders and global payments experts to its annual ACI Exchange Asia Pacific conference.
Sign-up for ACI Worldwide Spotlights Payments Disruption at Exchange Asia Pacific Customer Conference investment picks
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , and Retail Decisions (ReD) , a leader in fraud prevention solutions, today announced that they have entered into a definitive transaction agreement.
Sign-up for ACI Worldwide to Acquire ReD investment picks
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , today announced financial results for the period ended June 30, 2014.
Sign-up for ACI Worldwide, Inc. Reports Financial Results for the Quarter Ended June 30, 2014 investment picks
ACI Worldwide (NASDAQ: ACIW), a leading international provider of electronic payment and banking solutions , announced today that it will report its financial results for the second quarter 2014 on July 31, 2014.
Sign-up for ACI Worldwide, Inc. To Release Second Quarter 2014 Financial Results investment picks
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , today announced that the City of Baltimore (MD) can continue to provide city residents with a quick, simple and reliable way to manage and pay their bills, thanks to ACI’s electronic payment offerings.
Sign-up for ACI Worldwide’s Electronic Payment Offerings Improve Payment Experience for City of Baltimore investment picks
Acklands-Grainger Inc. Completes Acquisition Of WFS Enterprises Inc. Canada NewsWire TORONTO , Sept.
Sign-up for Acklands-Grainger Inc. Completes Acquisition Of WFS Enterprises Inc. investment picks
2014/8/14
-Sital S.
Sign-up for Ackman boosted Allergan stakes in Q2 investment picks
By David Benoit William Ackman, the activist investor, sent a letter to the board of Allergan Inc. on Wednesday excoriating the board for its response to his firm's joint-takeover proposal with Valeant Pharmaceuticals International Inc. The letter, reviewed by The Wall Street Journal, says Allergan (AGN) has violated its fiduciary duty by not negotiating over the $53 billion takeover offer from Valeant and Ackman's firm, which Allergan has rebuffed.
Sign-up for Ackman rebukes Allergan over response to Valeant bid investment picks
2014/8/5
Stafford, VA, Aug.
Sign-up for Acolyst | FalconStor Federal Team Proud to Sponsor 2014 Audi Best Buddies Challenge in Washington, D.C. investment picks
Results from a large-scale retrospective claims database study assessing real-world use of AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg will be presented by Acorda Therapeutics, Inc. (Nasdaq: ACOR ) and HealthCore Inc. at the 2014 Joint ACTRIMS-ECTRIMS Meeting.
Sign-up for Acorda Therapeutics and HealthCore to Present Real World Health Economics and Outcomes Data on Multiple Sclerosis Therapy AMPYRA investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced receipt of a Paragraph IV Certification Notice Letter advising that Actavis Laboratories FL, Inc. submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg.
Sign-up for Acorda Therapeutics Announces Notification of ANDA Filing for AMPYRA® investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced the pricing of a public offering of $300 million principal amount of convertible senior notes due 2021 (the "Notes"). The Notes will bear interest at an annual rate of 1.75% and will mature on June 15, 2021, unless earlier converted, purchased or redeemed.
Sign-up for Acorda Therapeutics Announces Pricing of $300 Million of 1.75% Convertible Senior Notes Due 2021 investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced its intention to offer, subject to market and other conditions, $300 million principal amount of convertible senior notes due 2021 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today.
Sign-up for Acorda Therapeutics Announces Public Offering of Convertible Senior Notes Due 2021 investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced its financial results for the second quarter ended June 30, 2014.
Sign-up for Acorda Therapeutics Reports Second Quarter 2014 Financial Results investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference to Acorda Therapeutics Reports Second Quarter 2014 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices